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Infectious Complications After Small Bowel Transplantation in Adults: 
an Update 
S. Kusne, H. Furukawa, K. Abu-Elmagd, W. Irish, J. Rakela, J. Fung, T.E. Starzl, and S. Todo 
WE have reported our experience with the first 21 adult patients after small bowel transplantation (Tx) on 
tacrolimus immunosuppression regimen in the Paris meet-
ing.1 The present report represents an update of the 
infectious complications that occurred in this patient pop-
ulation. 
METHODS 
Patient Population 
Between May 1990 and February 1995,29 adult patients underwent 
small bowel Tx in the Transplantation Institute, University of 
Pittsburgh. Fifteen patients underwent small bowel transplant 
(SBTx),8 had small bowel together with liver transplant (SBTx/L), 
and 6 patients underwent multi-visceral Tx (MY), which included 
SBTx/L together with other organs. In 11 patients (8 SBTx, 3 MY) 
Tx of the bowel included also colonic segment. Patients were 
prospectively followed for infectious complications using previous 
definitions of infection.2 
Immunosuppression 
Tacrolimus was given intravenol.lsly at 0.1 mglkg/day and later 
orally at 0.15 mglkg every 12 hours. Steroid induction was given 
with 1 gm methylprednisolone and steroid maintenance with 20 mg 
prednisone. Acute rejection was treated with a "bolus" or "recycle" 
of methylprednisolone. Steroid resistant rejection was treated with 
OKT3 monoclonal antibody. 
Prophylaxis 
Antimicrobial prophylaxis included intravenous ccfotaximc and 
ampicillin 4 gld for 3 days, oral nystatin 2 million units a day, 
intravenous ganciclovir IO/mg/kg/d, oral trimethoprim/sulfame-
thoxazule HO mgl400 mg a day, and selective bowel decontamina-
tion with colistin. gentamicin. and nystatin. 
RESULTS 
Twenty-nine adult patients underwent small bowel Tx and 
were prospectively followed for infectious complications. 
The median follow up was 643 days (Range 21 days to 4.7 
years). The mean age was 33 years (Range 19 to 58 years), 
and the Female/Male ratio was 1.2/1.0. The Kaplan-Meier 
I-year patient survival was 68% :!:: 9%. and overall mortality 
was 55% (16/29). Twenty-eight of 29 (97%) patients had at 
least one infectious episode. and the median number of 
infectious episodes was 5 per infected patient (Range I to 
11). The percentage of patients with bacterial infection was 
93%. viral infection 69%. and fungal infection 59%. The 
median number of episodes per infected patient in the three 
transplant types. SBTx. SBTxJL. MV. was 3.5. 5.0. and 6.5. 
respectively (P = .056. Kruskal-Wallis Test). The percent-
age of SBTx patients with hacterial infection at the first 3 
months after Tx with and without colonic segments was 
87% (7/8), and 43% (317), respectively (P = .20, Fisher 
Exact Test). 
There were total of 140 episodes of infection and their 
occurrence at 1 to 3 months, 4 to 6 months, and later than 
6 months following Tx was 40%, 16%, and 44%, respec-
tively. These included: bacterial (90): line infection (25), 
peritonitis (12), abdominal abscess (11), primary bactere-
mia (11), pneumonia (8), wound infection (8), Oostridium 
difficile colitis (6), others (9); viral (26): CMV (19), EBV 
(3), HSV (1). hepatitis C (3); fungal (20): candidiasis (16), 
aspergillosis (1), coccidioidomycosis (1), others (2); bacte-
riallfungal (4). Twenty-one of 29 (72%) patients had at least 
one episode of bacteremia or fungemia, and the median 
number of episodes was 2.0 (Range 1.0 to 7.0). The source 
of infection for these episodes of positive blood culture was: 
intravascular line (43%), abdomen (19%), others (11%). 
and unknown source (28%). There were total of 54 positive 
blood cultures which included: aerobic gram positive organ-
isms in 62%, aerobic gram negative organisms in 28%, 
anaerobic organisms in 2%, and candida species in 9%. 
Sixteen of 29 (55%) patients developed symptomatic CMV 
infection. Of these, 10 patients had primary infection, and 6 
patients had reactivation. These infections included: gastro-
enteritis (90%), hepatitis (5%), and retinitis (5%). 
DISCUSSION 
We reported in the past our experience with the first 21 
patients who underwent small bowel Tx at the University of 
Pittsburgh.' In this report we were able to summarize our 
experience in a larger group of patients with a longer 
follow-up. 
The rate of infectious complication after small bowel Tx 
is very high, and the risk of infection is still relatively high 
more than 6 months after Tx. There was a trend for a higher 
rate of infection in patients who underwent MV compared 
to patients who underwent SBTx or SBTxJL. There was also 
a trend of higher rate of early bacterial infections in patients 
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with SBTx with a colonic segment. Symptomatic CMV 
infection and bacteremia/fungemia were the most frequent 
infections. We have identified the vulnerability of the 
transplant gut to CMV, and its association with higher 
amounts of tacrolimus and steroids. 3.4 The high rate of 
bacteremiaJfungemia is mostly due to infection of central 
lines and abdomen. Bacterial translocation from the gut 
may explain in part those episodes of bacteremia with 
"unknown" source, and early bacterial infections in SBTx 
with colonic segment. 
Reduced infectious complications after small bowel 
transplantation is a very important goal. Possible strategies 
for the future are: preemptive therapy and limitation of 
transplant of CMV seronegative recipients with seroposi-
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tive organs, limitation of colonic segment transplant, paying 
special attention to management and maintenance of cen-
tral lines. and innovative strategies in immunosuppression 
therapy. 
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